Vitrolife AB
STO:VITR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
156.6
265.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vitrolife AB
Vitrolife AB
Capital Expenditures
Vitrolife AB
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vitrolife AB
STO:VITR
|
Capital Expenditures
-kr156m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Capital Expenditures
-kr48.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Capital Expenditures
-kr8.4m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Probi AB
STO:PROB
|
Capital Expenditures
-kr57.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-16%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Capital Expenditures
-kr3.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-42%
|
|
|
BioArctic AB
STO:BIOA B
|
Capital Expenditures
-kr7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Vitrolife AB
Glance View
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
See Also
What is Vitrolife AB's Capital Expenditures?
Capital Expenditures
-156m
SEK
Based on the financial report for Sep 30, 2024, Vitrolife AB's Capital Expenditures amounts to -156m SEK.
What is Vitrolife AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-15%
Over the last year, the Capital Expenditures growth was -53%. The average annual Capital Expenditures growth rates for Vitrolife AB have been -73% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
